SANTA CLARA, Calif., Nov. 13, 2023 /PRNewswire/ -- DeepSight™ Technology, a pioneering force in medical innovation, is thrilled to announce...
ATLANTA, GA and PRINCETON, NJ / ACCESSWIRE / November 13, 2023 / Florence Healthcare and WCG have announced a strategic...
ELKHORN, NE / ACCESSWIRE / November 13, 2023 / Fusion has announced a new scholarship program, Compassion in Care -...
Seasoned Leader Brings More than Two Decades of Medical Device Experience and Proven Track Record of Driving Growth and Organizational...
Surescripts leads nationwide interoperability, connecting more than 2 million care providers with virtually every American patient, supporting better informed careARLINGTON,...
Hospital medical equipment rental and service partner continues expansion to meet extraordinary demand from for on-demand access to equipment as...
Southlake, Texas, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”),...
PLEASANTON, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Healthcare Triangle, Inc. (Nasdaq: HCTI) (“HCTI” or the "Company"), a leader in...
Completed enrollment of 380 patients in pivotal Phase 3 trial of lead therapeutic cancer vaccine, IO102-IO103 in combination with KEYTRUDA®...
Dorothy Clarke Dorothy Clarke WOBURN, Mass., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA), a...
Data From Study Funded by NIH Presented at the American Heart Association Annual Meeting Oak Ridge, TN, Nov. 13, 2023...
NEW YORK, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal...
MARIETTA, Ga., Nov. 13, 2023 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that...
Results Suggest Formulation Potentially Suitable for At-Home Administration Ketabon Also Releases In-Depth Data from Phase 2 KET01 Trial MUNICH, Germany,...
-- BROADWAY Phase 3 trial enrollment completed; on-track to report topline data for Phase 3 BROOKLYN and BROADWAY trials in...
NEW YORK, Nov. 13, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune modulating...
Enrollment underway in Phase 1 trial with novel protease inhibitor CDI-988, the first potential dual coronavirus-norovirus oral antiviralDosing expected to...
Transformative capital raise of $88.2 million from leading healthcare investors provides funding for BET inhibitor programs through the end of...
Phase 1 clinical trial of APG777, a fully optimized, subcutaneous, extended half-life anti-IL-13 antibody, initiated ahead of schedule with initial...
No Material Impact on 2023 Financial Results; Reaffirms 2023 Outlook No Impact on Cash or Business Operations MURRAY, Utah, Nov....